Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Weekly Gemcitabine and Docetaxel Combination Therapy for Relapsed Ovarian or Peritoneal Cancer

NCT00227721 is registered in ClinicalTrials.gov with Robert Morris as lead sponsor.

NCT NCT00227721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00227721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Weekly Gemcitabine and Docetaxel Combination Therapy for Relapsed Ovarian or Peritoneal Cancer
Lead sponsor
Robert Morris
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2004
Completion date
February 28, 2017
Enrollment
30 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, peritoneal cavity cancer